Active Ingredient History
Colfosceril palmitate (dipalmitoylphosphatidylcholine) is a synthetic pulmonary surfactant, which is used in infants with respiratory distress syndrome it was approved in 1990, but nowadays it is under the state of canceled post-marketing. Colfosceril palmitate is reducing the tension and stabilizing the alveoli from collapsing. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Respiratory Distress Syndrome, Newborn (approved 2000)
Bronchopulmonary Dysplasia (Phase 2/Phase 3)
Cystic Fibrosis (Phase 2)
Infant, Low Birth Weight (Phase 2/Phase 3)
Infant, Newborn (Phase 2/Phase 3)
Infant, Premature (Phase 2/Phase 3)
Infant, Small for Gestational Age (Phase 2/Phase 3)
Meconium Aspiration Syndrome (Phase 3)
Obesity (Phase 2)
Premature Birth (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Respiratory Distress Syndrome, Newborn (Phase 2)
Respiratory Insufficiency (Phase 2)
Sleep Apnea, Obstructive (Phase 2)
Sleep Apnea Syndromes (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue